NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer
- Prof. Brown is a leading researcher in Transcranial Magnetic Stimulation (“TMS”) and currently serves as President of the Clinical TMS Society.
- His work explores how brain stimulation therapies can be enhanced through neuroplasticity-focused medications, including D-cycloserine, a component of NRx’s investigational drug NRX‑101.
- Brown previously received funding from the Defense Advanced Research Projects Agency (“DARPA”) to study treatments for military personnel suffering from Post-Traumatic Stress Disorder (“PTSD”).
- NRx is investigating a treatment approach combining ketamine, TMS, and hyperbaric oxygen in patients with PTSD and depression, with trials planned through its HOPE Therapeutics clinic network.
- The appointment reflects NRx’s evolving strategy to integrate neuroscience research and clinical deployment in treatments for severe central nervous system disorders.
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed neurostimulation researcher Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer, bringing a prominent academic voice in brain stimulation therapies into its leadership ranks (https://nnw.fm/N1PTD ).
The company is developing treatments targeting central nervous system disorders including suicidal depression and Post-Traumatic Stress Disorder (“PTSD”). Brown’s appointment signals a deeper focus on combining pharmacological approaches with device-based therapies designed to modify neural circuitry.
Brown is a psychiatrist, neurologist and neuroscientist whose work has focused on understanding the biological mechanisms behind Transcranial Magnetic Stimulation (“TMS”), a noninvasive brain-stimulation therapy used primarily to treat major depressive disorder. He serves as medical director of the TMS service at McLean Hospital and leads the Brain Stimulation Mechanisms Laboratory. Brown also holds an academic appointment as assistant professor of psychiatry at Harvard Medical School.
Within the field of brain stimulation, Brown has studied how targeted magnetic pulses can alter neural circuits involved in mood regulation. His research explores how these biological effects might be strengthened by drugs designed to enhance neuroplasticity, the brain’s ability to reorganize and form new neural connections.
Brown currently serves as president of the Clinical TMS Society and is founding editor-in-chief of the journal Transcranial Magnetic Stimulation, reflecting his role in shaping the field’s research agenda.
At NRx, Brown’s role will center on integrating academic neuroscience with the company’s drug development pipeline. A key area of overlap is the company’s investigational therapy NRX‑101, an oral combination of D-cycloserine and lurasidone designed to stabilize patients following acute treatment with ketamine.
Brown has previously investigated how D-cycloserine can enhance learning and neural adaptation processes associated with brain stimulation therapies. This concept, pairing TMS with neuroplasticity-enhancing drugs, forms part of the mechanistic rationale behind NRx’s clinical strategy.
The company is also developing NRX‑100, a preservative-free intravenous formulation of ketamine that has received Fast Track designation from the U.S. Food and Drug Administration for treating suicidal ideation in depression.
NRX-101 has been granted Breakthrough Therapy designation for suicidal bipolar depression, reflecting regulators’ interest in therapies addressing severe psychiatric conditions with limited treatment options.
Brown’s background includes research funded by the Defense Advanced Research Projects Agency, which supported work on how brain stimulation could be deployed to treat combat-related depression and PTSD among military personnel. The research aimed to explore whether TMS could be adapted for forward deployment in operational environments, potentially allowing treatment to be administered closer to the battlefield or within military medical facilities.
NRx executives say that experience aligns with their goal of developing therapies that could serve veterans and first responders experiencing severe psychological trauma.
According to the company, emerging evidence suggests that a combination of ketamine, TMS and hyperbaric oxygen therapy may help some individuals with PTSD return to work or active service. NRx has filed an Investigational New Drug application with the U.S. Food and Drug Administration to test that approach in combination with NRX-101. Clinical work related to that protocol is expected to occur through HOPE Therapeutics, a healthcare subsidiary of NRx that is building a network of interventional psychiatry clinics.
Brown, in a statement accompanying the announcement, said he intends to focus on applying insights from neuroscience laboratories and academic collaborations to scalable treatment models.
“Academic–industry partnerships are essential to closing the gap between discovery and real-world impact. While the burden of depression, anxiety, PTSD, and suicide continues to rise, we are simultaneously entering an era of novel, rapid, and effective treatments,” he said. “NRX is uniquely mission-driven in its commitment to alleviating suffering associated with these conditions, including its pioneering work translating TMS-pharmacologic augmentation strategies into real-world care. I am proud to contribute to this shared vision and look forward to advancing therapies that meaningfully change lives.”
For more information, visit the company’s website at www.NRxPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://nnw.fm/NRXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Prof. Brown is a leading researcher in Transcranial Magnetic Stimulation (“TMS”) and currently serves as President of the Clinical TMS Society.
- His work explores how brain stimulation therapies can be enhanced through neuroplasticity-focused medications, including D-cycloserine, a component of NRx’s investigational drug NRX‑101.
- Brown previously received funding from the Defense Advanced Research Projects Agency (“DARPA”) to study treatments for military personnel suffering from Post-Traumatic Stress Disorder (“PTSD”).
- NRx is investigating a treatment approach combining ketamine, TMS, and hyperbaric oxygen in patients with PTSD and depression, with trials planned through its HOPE Therapeutics clinic network.
- The appointment reflects NRx’s evolving strategy to integrate neuroscience research and clinical deployment in treatments for severe central nervous system disorders.
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed neurostimulation researcher Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer, bringing a prominent academic voice in brain stimulation therapies into its leadership ranks (https://nnw.fm/N1PTD ).
The company is developing treatments targeting central nervous system disorders including suicidal depression and Post-Traumatic Stress Disorder (“PTSD”). Brown’s appointment signals a deeper focus on combining pharmacological approaches with device-based therapies designed to modify neural circuitry.
Brown is a psychiatrist, neurologist and neuroscientist whose work has focused on understanding the biological mechanisms behind Transcranial Magnetic Stimulation (“TMS”), a noninvasive brain-stimulation therapy used primarily to treat major depressive disorder. He serves as medical director of the TMS service at McLean Hospital and leads the Brain Stimulation Mechanisms Laboratory. Brown also holds an academic appointment as assistant professor of psychiatry at Harvard Medical School.
Within the field of brain stimulation, Brown has studied how targeted magnetic pulses can alter neural circuits involved in mood regulation. His research explores how these biological effects might be strengthened by drugs designed to enhance neuroplasticity, the brain’s ability to reorganize and form new neural connections.
Brown currently serves as president of the Clinical TMS Society and is founding editor-in-chief of the journal Transcranial Magnetic Stimulation, reflecting his role in shaping the field’s research agenda.
At NRx, Brown’s role will center on integrating academic neuroscience with the company’s drug development pipeline. A key area of overlap is the company’s investigational therapy NRX‑101, an oral combination of D-cycloserine and lurasidone designed to stabilize patients following acute treatment with ketamine.
Brown has previously investigated how D-cycloserine can enhance learning and neural adaptation processes associated with brain stimulation therapies. This concept, pairing TMS with neuroplasticity-enhancing drugs, forms part of the mechanistic rationale behind NRx’s clinical strategy.
The company is also developing NRX‑100, a preservative-free intravenous formulation of ketamine that has received Fast Track designation from the U.S. Food and Drug Administration for treating suicidal ideation in depression.
NRX-101 has been granted Breakthrough Therapy designation for suicidal bipolar depression, reflecting regulators’ interest in therapies addressing severe psychiatric conditions with limited treatment options.
Brown’s background includes research funded by the Defense Advanced Research Projects Agency, which supported work on how brain stimulation could be deployed to treat combat-related depression and PTSD among military personnel. The research aimed to explore whether TMS could be adapted for forward deployment in operational environments, potentially allowing treatment to be administered closer to the battlefield or within military medical facilities.
NRx executives say that experience aligns with their goal of developing therapies that could serve veterans and first responders experiencing severe psychological trauma.
According to the company, emerging evidence suggests that a combination of ketamine, TMS and hyperbaric oxygen therapy may help some individuals with PTSD return to work or active service. NRx has filed an Investigational New Drug application with the U.S. Food and Drug Administration to test that approach in combination with NRX-101. Clinical work related to that protocol is expected to occur through HOPE Therapeutics, a healthcare subsidiary of NRx that is building a network of interventional psychiatry clinics.
Brown, in a statement accompanying the announcement, said he intends to focus on applying insights from neuroscience laboratories and academic collaborations to scalable treatment models.
“Academic–industry partnerships are essential to closing the gap between discovery and real-world impact. While the burden of depression, anxiety, PTSD, and suicide continues to rise, we are simultaneously entering an era of novel, rapid, and effective treatments,” he said. “NRX is uniquely mission-driven in its commitment to alleviating suffering associated with these conditions, including its pioneering work translating TMS-pharmacologic augmentation strategies into real-world care. I am proud to contribute to this shared vision and look forward to advancing therapies that meaningfully change lives.”
For more information, visit the company’s website at www.NRxPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://nnw.fm/NRXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
